Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents

A system for treating a patient with cancer within a body lumen, the system comprising:

• an implant configured for endoluminal placement via the delivery system into the body lumen of the patient, wherein the implant comprises:
• a therapeutic member comprising a treatment portion for controlled release of a chemotherapeutic agent, the treatment portion comprising:
• a therapeutic region comprising the chemotherapeutic agent, a polymer and a releasing agent, wherein the chemotherapeutic agent, the polymer,
• and the releasing agent are mixed together, wherein the releasing agent is configured to dissolve when the therapeutic member is placed in vivo to form channels in the control region;
• a substantially impermeable base region,
• wherein the treatment portion is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region;
• and
• an anchoring member configured to provide structural support for the therapeutic member following endoluminal placement of the implant,
• wherein the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the implant in the body lumen of the patient.

An esophageal stent system for treating a patient with esophageal cancer, the esophageal stent system comprising:

• a delivery system;
• an implant configured for endoluminal deployment via the delivery system into the esophagus of the patient, wherein the implant comprises:
• a therapeutic member having a treatment portion comprising a film for controlled release of a chemotherapeutic agent, the film comprising:
• a control region comprising a bioresorbable polymer and a releasing agent mixed with the bioresorbable polymer, wherein the releasing agent is configured to dissolve when the therapeutic member is placed in vivo to form diffusion channels in the control region;
• a therapeutic agent region comprising the chemotherapeutic agent mixed with the bioresorbable polymer and the releasing agent;
• a substantially impermeable base region comprising the bioresorbable polymer, and
• wherein the film is configured to release the chemotherapeutic agent in a direction away from the substantially impermeable base region;
• a stent configured for expansion during endoluminal deployment of the implant,
• wherein the delivery system is configured to enable a treatment provider to position the treatment portion of the therapeutic member proximate to a treatment site corresponding to a tumor in the esophagus of the patient, and
• wherein the treatment portion of the therapeutic member is configured to administer a therapeutically effective dose to the treatment site for a sustained period following endoluminal placement of the implant in the esophagus of the patient, and
• wherein the stent is configured to provide structural support to the treatment site following endoluminal deployment of the implant, and
• wherein the therapeutic member and stent are configured to provide a synergistic combination of chemotherapeutic agent and structural support to the treatment site.